Targeting mutant p53 through the mevalonate pathway
- PMID: 27784901
- DOI: 10.1038/ncb3435
Targeting mutant p53 through the mevalonate pathway
Abstract
It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous